Second Line Breast Cancer Trial
Study identifier:9238IL/0021
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Double-Blind, Randomized, Multi-center Trial comparing the Efficacy and Tolerability of 125 and 250mg of Faslodex (Long acting ICI 182,780) with 1mg Arimidex (Anastrazole) in Postmenopausal Women with Advanced Breast Cancer.
Medical condition
Advanced breast cancer
Phase
Phase 3
Healthy volunteers
No
Study drug
Fulvestrant, Anastrozole
Sex
Female
Actual Enrollment
588
Study type
Interventional
Age
18 Years - 150 Years
Date
Study Start Date: 01 May 1997
Primary Completion Date: -
Study Completion Date: 01 Sept 2004
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Faslodex 125mg and Arimidex 1 mg | Drug: Fulvestrant 125mg Other Name: Faslodex Drug: Anastrozole ARIMIDEX |
| Experimental: 2 Faslodex 250mg and Arimidex 1mg | Drug: Anastrozole ARIMIDEX Drug: Fulvestrant 250mg Other Name: Faslodex |
Contacts
Investigators
Principal Investigator
Guido Hoctin-Boes
Astra Zeneca
